Onconetix, Inc. Impairment of Long-Lived Assets to be Disposed of
Onconetix, Inc. (ONCO) reported Impairment of Long-Lived Assets to be Disposed of of $3.53 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf · last filed 2026-03-13
- Onconetix, Inc. impairment of long-lived assets to be disposed of for the quarter ending 2024-12-31 was $1.00.
- Onconetix, Inc. impairment of long-lived assets to be disposed of for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- Onconetix, Inc. impairment of long-lived assets to be disposed of for the quarter ending 2024-06-30 was $1.24M.
- Onconetix, Inc. impairment of long-lived assets to be disposed of for the quarter ending 2024-03-31 was $2.29M.
- Onconetix, Inc. impairment of long-lived assets to be disposed of for fiscal 2024 was $3.53M, a 1222.27% increase from fiscal 2023.
- Onconetix, Inc. impairment of long-lived assets to be disposed of for fiscal 2023 was $267.02K.
| Period end | Impairment of Long-Lived Assets to be Disposed of 3 month | Impairment of Long-Lived Assets to be Disposed of 6 month | Impairment of Long-Lived Assets to be Disposed of 9 month | Impairment of Long-Lived Assets to be Disposed of 9 month as first filed | Impairment of Long-Lived Assets to be Disposed of 12 month | Impairment of Long-Lived Assets to be Disposed of 12 month as first filed |
|---|---|---|---|---|---|---|
| 2024-12-31 | $1.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $1.00 derived: sum of 2 quarters · filed 2026-03-13 | $1.24M derived: sum of 3 quarters · filed 2026-03-13 | $3.53M 10-K · filed 2026-03-13 | ||
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $1.24M derived: sum of 2 quarters · filed 2025-11-13 | $3.53M 10-Q · filed 2025-11-13 | $3.53M derived: sum of 4 quarters · filed 2025-11-13 | ||
| 2024-06-30 | $1.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $3.53M 10-Q · filed 2025-08-14 | $3.53M derived: sum of 3 quarters · filed 2025-08-14 | $3.80M derived: sum of 4 quarters · filed 2025-08-14 | ||
| 2024-03-31 | $2.29M 10-Q · filed 2025-06-12 | $2.29M derived: sum of 2 quarters · filed 2025-06-12 | $2.56M derived: sum of 3 quarters · filed 2025-06-12 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-06-02 | $267.00K derived: sum of 2 quarters · filed 2025-06-02 | $267.02K 10-K · filed 2025-06-02 | $267.00K 10-K · filed 2024-04-11 | ||
| 2023-09-30 | $267.00K 10-Q · filed 2023-11-17 | $267.02K 10-Q · filed 2024-12-10 | $267.00K 10-Q · filed 2023-11-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |